Alto Neuroscience CFO exercises options for 55K shares

The option's vesting terms provided for 25% on September 8, 2022, followed by monthly installments subject to continuous service.

Rhea-AI Filing Summary

Alto Neuroscience, Inc. President and CFO Nicholas Conrad Smith exercised options for 55,000 common shares on October 2, 2026, at an exercise price of $2.32 per share. Following the transaction, he reported 79,060 directly held common shares and 57,405 options.

The option terms state that 25% of the underlying shares vested on September 8, 2022, with one forty-eighth (1/48th) vesting or to vest in monthly installments thereafter, subject to continuous service through each vesting date.

Insider Trade Summary

55,000 shares exercised/converted

Exercise 2 txns

Insider Smith Nicholas Conrad

Role PRESIDENT AND CFO

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Buy) F1	55,000	$0.00	$0.00
Exercise	Common Stock	55,000	$2.32	$128K

Holdings After Transaction: Employee Stock Option (Right to Buy) — 57,405 contracts (Direct); Common Stock — 79,060 shares (Direct)

Footnotes (1)

1. F1. 25% of the shares underlying the option vested on September 8, 2022, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Key Figures

Options exercised: 55,000 shares Exercise price: $2.32 per share Common shares after transaction: 79,060 shares +1 more

4 metrics

Options exercised 55,000 shares October 2, 2026

Exercise price $2.32 per share Option exercise on October 2, 2026

Common shares after transaction 79,060 shares Direct holdings

Options after transaction 57,405 options Reported following the transaction

Key Terms

Employee Stock Option (Right to Buy), one forty-eighth (1/48th), continuous service

3 terms

Employee Stock Option (Right to Buy) financial

"Employee Stock Option (Right to Buy)"

one forty-eighth (1/48th) financial

"one forty-eighth (1/48th) of the shares underlying the option"

continuous service financial

"subject to the Reporting Person's continuous service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ANRO shares did the President and CFO acquire through the option exercise?

Nicholas Conrad Smith acquired 55,000 common shares through an option exercise on October 2, 2026, at an exercise price of $2.32 per share. His reported direct holdings after the transaction were 79,060 common shares.

What was the vesting schedule for Nicholas Conrad Smith's ANRO option?

25% of the shares underlying the option vested on September 8, 2022, and one forty-eighth (1/48th) vested or was to vest in monthly installments thereafter. Each vesting installment was subject to the reporting person's continuous service through that vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/05/2026 - 04:59 PM Accepted by SEC EDGAR 10/05/2026 - 04:59 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Nicholas Conrad

(Last) (First) (Middle)

C/O ALTO NEUROSCIENCE, INC.

650 CASTRO STREET, SUITE 450

(Street)

MOUNTAIN VIEW CALIFORNIA 94041

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alto Neuroscience, Inc. [ ANRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/02/2026		M		55,000	A	$2.32	79,060	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$2.32	10/02/2026		M			55,000	(1)	09/08/2031	Common Stock	55,000	$0	57,405	D

Explanation of Responses:

1. 25% of the shares underlying the option vested on September 8, 2022, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

	/s/ Erin R. McQuade, Attorney-in-Fact	10/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)